睿知中国医院研究地图
候选清单

即将招募食管鳞状细胞癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06136988,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Active malignancy within 5 years prior to the first dose, except esophageal carcinoma studied in this trial and any locally curable tumor that has received radical therapy (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or early-stage thyroid cancer, etc).

    排除标准第 1 条

    Patients with active Hepatitis B (Hepatitis B surface antigen (HBsAg) or HBcAb positive test and active stage of Hepatitis B (HBV-DNA ≥ 10\^4 cps/mL or ≥ 2000 IU/mL)); Hepatitis C (Hepatitis C Antibody (Anti-HCV) positive test and a positive PCR result for HCV RNA); positive for HIV, during the screening period.

    排除标准第 15 条

  3. Have received potent inhibitors or potent inducers of CYP2C8 (for Phase Ⅱ trials only) or CYP3A4 within 14 days prior to the first dose.

    排除标准第 20 条

    Patients who have received antitumor therapy such as other clinical investigational drugs within 28 days prior to the first dose.

    排除标准第 23 条

    Patients who have received systemic glucocorticoid therapy (dose > 10 mg/day of prednisone or equivalent) within 28 days prior to the first dose.

    排除标准第 24 条

  4. ECOG score of 0-1 within 7 days prior to the first dose.

    入选标准第 4 条

  5. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L

    入选标准第 6 条

    Platelet count (PLT) ≥ 100×10\^9/L

    入选标准第 7 条

    Hemoglobin ≥ 80g/L

    入选标准第 8 条

    Total bilirubin ≤1.0×ULN; ALT/AST ≤1.5×ULN

    入选标准第 10 条

    Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min, Cockcroft-Gault formula

    入选标准第 11 条

    Activated Prothrombin Time (APTT) and International Normalized Ratio (INR) ≤ 1.5 x ULN.

    入选标准第 12 条

  6. Have at least one evaluable lesion per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).

    入选标准第 14 条

  7. Female patients of childbearing age tested negative serum pregnancy test within 7 days prior to the first dose, and patients must agree to take effective contraception from the signing of the informed consent form until 6 months after the last dose, during which time breastfeeding is not allowed; male patients must agree to take contraception and sperm donation is not allowed.

    入选标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06136988,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years (based on the day of signing the informed consent form).
  2. Voluntarily sign the informed consent, willing and able to follow the protocol for visits, treatment and laboratory tests.
  3. Locally advanced (stage II-IVa and IVb supraclavicular lymph node metastases according to AJCC 8th edition) esophageal squamous carcinoma (in the case of mixed adenosquamous carcinoma, more than 50% squamous carcinoma component can be screened) diagnosed histologically or cytologically, which is unresectable in the judgment of the principal investigator, and is amenable to definitive chemoradiotherapy (dCRT) .
  4. ECOG score of 0-1 within 7 days prior to the first dose.
  5. Vital organ function within 7 days prior to first dose, meeting the following criteria (no blood transfusions, no use of human granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), and erythropoietin (EPO) within 14 days prior to the first dose):
  6. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
  7. Platelet count (PLT) ≥ 100×10\^9/L
  8. Hemoglobin ≥ 80g/L
  9. Serum albumin ≥ 28g/L
  10. Total bilirubin ≤1.0×ULN; ALT/AST ≤1.5×ULN
  11. Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min, Cockcroft-Gault formula
  12. Activated Prothrombin Time (APTT) and International Normalized Ratio (INR) ≤ 1.5 x ULN.
  13. Female patients of childbearing age tested negative serum pregnancy test within 7 days prior to the first dose, and patients must agree to take effective contraception from the signing of the informed consent form until 6 months after the last dose, during which time breastfeeding is not allowed; male patients must agree to take contraception and sperm donation is not allowed.
  14. Have at least one evaluable lesion per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).

排除标准:Exclusion Criteria:

  1. Active malignancy within 5 years prior to the first dose, except esophageal carcinoma studied in this trial and any locally curable tumor that has received radical therapy (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or early-stage thyroid cancer, etc).
  2. History of esophageal perforation and/or esophageal fistula within 6 months prior to the first dose; or significant tumor invasion into an organ adjacent to the esophageal lesion (aorta or trachea), etc., resulting in a high risk of hemorrhage, esophageal fistula, or signs of esophageal perforation.
  3. Uncontrollable plasma effusions requiring frequent drainage or medical intervention (e.g., pleural effusion, peritoneal effusion, pericardial effusion, etc.) within 7 days prior to the first dose that require additional interventions within 2 weeks of the intervention (excluding exfoliative cytology of the exudate).
  4. Weight loss of 20% or more within 3 months prior to the first dose; or BMI <18.5 kg/m\^2 and/or weight <30 kg.
  5. Severe allergy history to albumin or docetaxel, paclitaxel, cisplatin, or monoclonal antibody drugs.
  6. Patients who have received prior antitumor therapy for esophageal cancer.
  7. Patients with immunodeficiency or active autoimmune disease (except a. well-controlled type I diabetes b. hypothyroidism [controlled with hormone replacement therapy] c. well-controlled celiac disease d. dermatologic that do not require systemic therapy [e.g., vitiligo, psoriasis, alopecia] e. any other condition not expected to recur in the absence of external triggers).
  8. History of severe cardiovascular disease within 6 months prior to the first dose, including but not limited to:
  9. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, Third-degree atrioventricular block
  10. History of myocardial infarction, unstable angina, angioplasty, coronary artery bridging surgery
  11. Heart failure with New York Heart Association (NYHA) classification of class III and above
  12. Left ventricular ejection fraction (LVEF) <50% at screening period
  13. Patients with prolonged QT/QTc interval on ECG at baseline (QTcF > 480ms, Fridericia formula: QTcF=QT/RR\^0.33, RR=60/heart rate).
  14. Patients with poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during the screening period).
  15. Patients with active Hepatitis B (Hepatitis B surface antigen (HBsAg) or HBcAb positive test and active stage of Hepatitis B (HBV-DNA ≥ 10\^4 cps/mL or ≥ 2000 IU/mL)); Hepatitis C (Hepatitis C Antibody (Anti-HCV) positive test and a positive PCR result for HCV RNA); positive for HIV, during the screening period.
  16. Patients with poorly controlled diabetes mellitus, or hypokalemia, hyponatremia, or abnormal values on corrected calcium lab tests (CTCAE 5.0 >1 grade) despite of standard drug therapy within 14 days prior to the first dose.
  17. History of interstitial lung disease or non-infectious pneumonia.
  18. Patients with known psychoneurologic disorders that may affect adherence to the trial, and those with a history of drug dependence;
  19. Patients with severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to the first dose. Note: Antiviral therapy for patients with viral hepatitis is permitted.
  20. Have received potent inhibitors or potent inducers of CYP2C8 (for Phase Ⅱ trials only) or CYP3A4 within 14 days prior to the first dose.
  21. Vaccination with a live or live attenuated vaccine (inactivated vaccines are permitted) within 28 days prior to the first dose.
  22. History of major organ surgery (excluding puncture biopsy) within 28 days prior to the first dose.
  23. Patients who have received antitumor therapy such as other clinical investigational drugs within 28 days prior to the first dose.
  24. Patients who have received systemic glucocorticoid therapy (dose > 10 mg/day of prednisone or equivalent) within 28 days prior to the first dose.
  25. Any condition that, in the opinion of the investigator, makes participation in the study inappropriate (including, but not limited to, concurrent serious or uncontrolled medical conditions, potential safety risks, interference with the interpretation of the results of the study, and adherence to the trial).
  26. The patient is concurrently participating in another clinical study, unless it is an observational (non-interventional) clinical study or is in the follow-up period of an interventional study.

引自 ClinicalTrials.gov, NCT06136988, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06136988,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06136988